Monsanto

Monsanto Views Bayer’s Current Proposal as Incomplete and Financially Inadequate

A follow up to share Monsanto’s public response to Bayer AG’s unsolicited proposal to acquire Monsanto for $122 per share in cash. Monsanto believes that Bayer’s current proposal is “incomplete and financially inadequate but is open to discussing a potential path forward that would create appropriate value for MON shareholders.

The price currently undervalues Monsanto and its future growth prospects. Additionally, it doesn’t take into consideration several additional factors, which include:  its leading position in seeds & traits, unparalleled data science platform and robust R&D pipeline, contributing to the scale and efficiency to unlock yield for farmers. These, coupled with the Company’s financial discipline, allow Monsanto to be best positioned to capitalize on the agriculture cycle as it rebounds, the company believes – bellow is the press release.

Monsanto –  Views Bayer’s Current Proposal as Incomplete and Financially Inadequate; Company Open to Discussing Potential Path Forward That Would Create Appropriate Value for Monsanto Shareowners

Tuesday May 24, 2016

“We believe in the substantial benefits an integrated strategy could provide to growers and broader society, and we have long respected Bayer’s business”

  • LOUIS–(BUSINESS WIRE)–Monsanto Company (NYSE: MON) today announced that its Board of Directors unanimously views the Bayer AG proposal as incomplete and financially inadequate, but is open to continued and constructive conversations to assess whether a transaction in the best interest of MON shareowners can be achieved.

“We believe in the substantial benefits an integrated strategy could provide to growers and broader society, and we have long respected Bayer’s business,” said Hugh Grant, MON Chairman and CEO. “However, the current proposal significantly undervalues our company and also does not adequately address or provide reassurance for some of the potential financing and regulatory execution risks related to the acquisition.”

There is no assurance that any transaction will be entered into or consummated, or on what terms. The MON Board of Directors has not set a timeline for further discussions and Monsanto does not intend to make further comment at this time.

Morgan Stanley & Co. and Ducera Partners are acting as financial advisors, and Wachtell, Lipton, Rosen & Katz is acting as legal advisor, to MON.

Monsanto

LEAVE A COMMENT


Saved Articles
X
TextTExtLInkTextTExtLInk

The Life and Career of Charlie Munger

Charlie is more than just Warren Buffett’s friend and Berkshire Hathaway’s Vice Chairman – Buffett has actually credited him with redefining how he looks at investing. Now you can learn from Charlie firsthand via this incredible ebook and over a dozen other famous investor studies by signing up below:

  • Learn from the best and forever change your investing perspective
  • One incredible tidbit of knowledge after another in the page-turning masterpiece of a book
  • Discover the secrets to Charlie’s success and how to apply it to your investing
Never Miss A Story!
Subscribe to ValueWalk Newsletter. We respect your privacy.

Congrats! Are you a smart person?

We have an exclusive targeted & limited time offer for being a sophisticated and loyal reader.

ValueWalkPremium is a website and newsletter on the latest industry news much of which is not in the public domain and obtained via our sources.

We also have 10 years of resources on how to use this information to better your investment process.

Sign up for  today and get our exclusive content for 40% off. This is our second biggest discount ever!!

Use coupon code VIP20 or click on the button below

Limited time offer only ENDS 3/31/2020 or after the next 45 subscribers take advantage whichever comes first – please do not share this discount with others

 

0